Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant camrelizumab plus chemotherapy for thoracic esophageal squamous cell carcinoma with cervical lymph node metastasis
ChiCTR2500097269Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel and tegafur in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 1-year disease-free survival. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
camrelizumabpaclitaxeltegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500097269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097269.